NJ-BURGISS/CAISSA
13.9.2021 14:17:05 CEST | Business Wire | Press release
The Burgiss Group, LLC (“Burgiss”) and Caissa, LLC (“Caissa”) today announced that they have entered into a definitive agreement to merge businesses. On a combined basis, the firm will be one of the world’s leaders in private capital and total investment plan solutions. Burgiss and Caissa’s products meet the challenges institutional investors face in managing asset allocation and liquidity and assessing exposure, performance, and risk, while addressing compliance, ESG and climate concerns. The combined firm will be headquartered in Hoboken, New Jersey and have over 450 employees worldwide.
“We’re excited to announce that Burgiss and Caissa are joining forces,” said James Kocis, Founder and CEO of Burgiss. “Caissa is a world-class provider of multi-asset class solutions to institutional investors. We’re thrilled to have our teams coming together and welcome the contributions that David Hsu and Susan Veksler will make to our business as members of our Board.”
“Burgiss and Caissa are a perfect match,” said David Hsu, Co-Founder and CEO of Caissa. “Both firms have their roots in helping investors make better investment decisions. Burgiss has an unrivaled presence and reputation in private capital data and analytics, while the Caissa platform serves as the foundational technology for investors across all asset classes. With our combined operational scale, we’re now able to deliver value to a wider audience much more quickly.”
“Caissa’s multi-asset class platform was expressly built for asset allocators,” said Susan Veksler, Co-Founder and President of Caissa. “As our clients know, we have taken great care to craft a solution that is both advanced and intuitive. Together with Burgiss, we will continue to advance the interests of our client base and remain at the forefront of innovation across data, analytics, and technology.”
This merger builds on Burgiss’ strategic partnership with MSCI Inc. (“MSCI”), a leading provider of critical decision support tools and services for the global investment community, announced in January 2020. Together, Burgiss and MSCI aim to drive innovation, acceleration and adoption of data, tools and solutions for investors in private assets around the world.
“The powerful combination of Burgiss and Caissa represents an exciting opportunity for investors and managers of private assets and multi-asset class portfolios around the world,” said Henry Fernandez, Chairman and CEO of MSCI. “With this merger, both firms can achieve tremendous scalability and drive greater innovation of differentiated tools and solutions across the global private assets industry. Through its representation on the Burgiss Board, MSCI looks forward to working closely together with Burgiss and Caissa to help them achieve their strategic objectives,” added Mr. Fernandez.
About Burgiss
Burgiss is the global provider of investment decision support tools for private capital. Along with deep expertise in performance and risk measurement, our analytics platform and research-quality data help investment teams make better investment decisions. Following the merger, Burgiss content and capabilities will continue to be accessible through multiple channels and platforms. We serve over 1,000 firms in 36 countries, and our data covers over $8 trillion in private capital.
About Caissa
Caissa is the leading portfolio analytics software provider for endowments, foundations, family offices, pension funds, and outsourced CIOs. Founded in 2010, the Caissa team is committed to advancing technology solutions for institutional allocators. Caissa's client base consists of asset owners representing over $1.7 trillion in assets under management. For more information, please visit www.caissallc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005161/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom